PMID- 23331339
OWN - NLM
STAT- MEDLINE
DCOM- 20130507
LR  - 20151119
IS  - 1365-2796 (Electronic)
IS  - 0954-6820 (Linking)
VI  - 273
IP  - 4
DP  - 2013 Apr
TI  - Sitagliptin improves beta-cell function in patients with acute coronary syndromes 
      and newly diagnosed glucose abnormalities--the BEGAMI study.
PG  - 410-21
LID - 10.1111/joim.12032 [doi]
AB  - BACKGROUND: Newly detected impaired glucose tolerance (IGT) or type 2 diabetes 
      mellitus (T2DM) are common in patients with acute coronary syndrome (ACS; i.e. 
      unstable angina/myocardial infarction) and related to disturbed beta-cell 
      function. The aim of this study is to test the hypothesis that treatment with a 
      dipeptidyl peptidase-4 inhibitor initiated soon after a coronary event improves 
      beta-cell function. METHODS: Acute coronary syndrome ACS patients with IGT or 
      T2DM (n = 71), screened by oral glucose tolerance test (OGTT) 4-23 days (median 6 
      days) after hospital admission, were randomly assigned to sitagliptin 100 mg (n = 
      34) or placebo (n = 37) and treated for a duration of 12 weeks. All patients 
      received lifestyle advice but no glucose-lowering agents other than the study 
      drug. The study end-point was beta-cell function assessed using the insulinogenic 
      index (IGI = DeltaInsulin30 /DeltaGlucose30 ), derived from an OGTT, and acute insulin 
      response to glucose (AIRg) assessed by a frequently sampled intravenous glucose 
      tolerance test. RESULTS: The IGI and AIRg did not differ at baseline between the 
      sitagliptin and placebo groups (69.9 vs. 66.4 pmol mmol(-1) and 1394 vs. 1106 
      pmol L(-1) min(-1) respectively). After 12 weeks, the IGI was 85.0 in the 
      sitagliptin and 58.1 pmol/mmol in the placebo group (P = 0.013) and AIRg was 1909 
      and 1043 pmol L(-1) min(-1) (P < 0.0001) in the sitagliptin and placebo groups 
      respectively. Fasting glucose at baseline was 6.1 mmol L(-1) in 
      sitagliptin-treated patients and 6.0 mmol L(-1) in those who received placebo 
      compared with 5.8 and 5.9 mmol L(-1) respectively, after 12 weeks of treatment. 
      Post load glucose metabolism improved in significantly more sitagliptin-treated 
      patients compared with the placebo group (P = 0.003). Sitagliptin was well 
      tolerated. CONCLUSION: Sitagliptin improved beta-cell function and glucose 
      perturbations in patients with ACS and newly diagnosed glucose disturbances.
CI  - (c) 2013 The Association for the Publication of the Journal of Internal Medicine.
FAU - Hage, C
AU  - Hage C
AD  - Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, 
      Sweden. camilla.hage@karolinska.se
FAU - Brismar, K
AU  - Brismar K
FAU - Efendic, S
AU  - Efendic S
FAU - Lundman, P
AU  - Lundman P
FAU - Ryden, L
AU  - Ryden L
FAU - Mellbin, L
AU  - Mellbin L
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130214
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrazines)
RN  - 0 (Triazoles)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*complications/diagnosis
MH  - Blood Glucose/drug effects/*metabolism
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Glucagon-Like Peptide 1/administration & dosage
MH  - Glucose Intolerance/complications/*diagnosis/drug therapy
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Insulin-Secreting Cells/drug effects/*metabolism
MH  - Prospective Studies
MH  - Pyrazines/*administration & dosage
MH  - Sitagliptin Phosphate
MH  - Treatment Outcome
MH  - Triazoles/*administration & dosage
EDAT- 2013/01/22 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/01/22 06:00
PHST- 2013/01/22 06:00 [entrez]
PHST- 2013/01/22 06:00 [pubmed]
PHST- 2013/05/08 06:00 [medline]
AID - 10.1111/joim.12032 [doi]
PST - ppublish
SO  - J Intern Med. 2013 Apr;273(4):410-21. doi: 10.1111/joim.12032. Epub 2013 Feb 14.